Investors

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces early studies of its weight management formulation in fruit yoghurts.

OptiBiotix, incorporated its weight management formulation into fruit yoghurts which were manufactured by NIZO food research BV (NIZO). NIZO has specialist expertise in the manufacture of dairy products and in using taste and texture to improve satiation (the feeling of fullness). The aim of the study was to assess product manufacturability and to ensure OptiBiotix's ingredients did not impact negatively on a dairy product's look, texture and taste. An organoleptic (tasting) panel reported the yoghurt products had a smooth feel and taste and had the appearance of conventional yoghurts.

Additional patent filings on this formulation are now underway prior to commencing discussions with potential partners to carry out nutritional studies and then manufacture and distribute the resulting portfolio of products.

Stephen O'Hara, CEO of OptiBiotix, commented: "These studies are encouraging and show early potential for incorporating OptiBiotix's proprietary weight management formulation into dairy products such as yoghurts. This supports our aim of extending the range of food types which can incorporate our weight management formulation, increasing the number of products and partnering opportunities. This will help OptiBiotix build a valuable and sustainable business and support governments around the world in the fight against obesity."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

About NIZO - www.nizo.com

NIZO is one of the most advanced, independent contract research companies in the world and works with both small and multinational food and ingredient companies to develop and produce innovative products for the food and drink industry. NIZO has one of the largest food-grade pilot plants in Europe, and more than 65 years' experience and expertise in product manufacture.